Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ADAP automation
October 2019
SHARING OPTIONS:

RENO, Nev.—Hamilton Company and Enable Biosciences announced a collaboration this summer to offer fully automated processing of up to 96 liquid biopsy samples simultaneously using an ultra-sensitive, highly specific immunoassay in a hands-free workflow. The assay in question is currently available for research applications for type 1 diabetes, Lyme disease, allergy testing and HIV testing. The qPCR-based assay technology, developed by Enable Biosciences, is known as Antibody Detection by Agglutination PCR (ADAP). It uses synthetic antigen-DNA conjugates to detect antibodies in liquid biopsy samples with 1,000- to 10,000-fold greater sensitivity than other single or multiplex assays. Automating the ADAP assay workflow on Hamilton’s Microlab STAR automated workstation increases sample throughput and significantly decreases active user labor time. The partners will co-promote this technology combination.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.